Chai Discovery has closed a $400 million Series C financing round led by Index Ventures, pushing the AI-driven drug discovery company to a post-money valuation of $3.8 billion — nearly triple its valuation from roughly seven months prior. The raise brings total capital secured across three rounds to more than $600 million in approximately eleven months, following a $70 million Series A and a $130 million Series B completed less than a year earlier.
Chai Discovery’s $400 million Series C values the AI drug discovery company at $3.8 billion — nearly triple its valuation from seven months prior.
Index Ventures led the round alongside returning backers Kleiner Perkins, Sequoia Capital, and Dimension. New investors entering the syndicate included Bain Capital Ventures, Battery Ventures, and Baillie Gifford. Additional participants included BDT & MSD, Sapphire Ventures, Avra Capital, Thrive Capital, Oak HC/FT, Menlo Ventures, General Catalyst, Glade Brook, Avenir, Lachy Groom, and Yosemite, the fund backed by Reed Jobs. The breadth of the investor group reflects sustained venture capital conviction in AI-native platforms targeting pharmaceutical drug discovery.
Chai Discovery builds generative AI software for biomolecule design, with a focus on therapeutic antibodies and other complex drug modalities. Its platform uses AI models to predict and reprogram biochemical molecule interactions, enabling rational design of novel drug candidates without relying exclusively on traditional high-throughput wet-lab screening.
The technology supports de novo antibody discovery and is designed to simultaneously optimize molecules across affinity, developability, and specificity — parameters critical to advancing drug candidates efficiently through early-stage development.
The Series C proceeds are earmarked to advance and scale the company’s proprietary generative AI software, expand platform capabilities, and support growing commercial operations. Chai Discovery‘s partnerships with large pharmaceutical companies have become a central part of its commercial model and a source of real-world data that feeds back into model refinement.
On the partnership front, Chai Discovery announced a collaboration with Novartis immediately alongside the Series C disclosure. The company also holds strategic agreements with argenx and Novartis for de novo antibody discovery across multiple therapeutic targets. Existing alliances with Pfizer and Eli Lilly further establish the platform’s utility at industrial scale.
These relationships serve dual purposes: generating commercial revenue and creating data feedback loops that are expected to strengthen model performance over time. The platform’s focus on “hard to drug” and undruggable medical conditions addresses some of the most pressing unmet needs in areas such as certain cancers and neurodegenerative diseases.
The rapid appreciation in Chai Discovery’s valuation — from a markedly lower figure less than a year ago to $3.8 billion — reflects both the pace of platform development and growing pharmaceutical industry demand for AI-driven alternatives to conventional discovery methods. Rather than supplementing legacy workflows incrementally, Chai Discovery positions its technology as a structural replacement for early-stage drug design processes that have historically been expensive, slow, and low in predictive accuracy.
The company’s ability to attract pharmaceutical partners of Novartis and Pfizer’s scale suggests the platform has moved beyond proof-of-concept into applied commercial use.
